

Secondary Trading Notice

Secondary Trading Notice (the “Notice”) Pursuant to Paragraph 708A (5) (e) of the Corporations Act 2001 (the “Act”)

The Act restricts the on-sale of securities issued without disclosure, unless the sale is exempt under section 708 or 708A of the Act.

By giving this notice, a sale of shares noted in the Appendix 2A dated 11 June 2021 and lodged on the ASX on that date (“Shares”) will fall within exemption in section 708A(5) of the Act.

The Company hereby notifies ASX under paragraph 708A (5) (e) of the Act that:

- (a) The Company has issued the Shares without disclosure to investors under Part 6D.2 of the Act;
- (b) as at the date of this Notice, the Company has complied with provisions of Chapter 2M of the Act as they apply to the Company, and section 674 of the Act; and;
- (c) as at the date of this Notice, there is no excluded information of the type referred to in sections 708A(7) and 708A(8) of the Act.

Authority by

This announcement has been authorised for release in accordance with the delegated authority of the Board of Resonance Health Limited.

For further Information please contact:

Mitchell Wells
Company Secretary, Resonance Health
E: mitchellw@resonancehealth.com P: +61 (0)8 9286 5300